Search
Phosphocreatine
go.drugbank.com/drugs/DB13191InvestigationalNutraceuticalIt is primarily found endogenously in the skeletal muscles of vertebrates where it serves a critical role as a rapidly acting energy buffer for muscle cell actions like contractions via its ability to
Difamilast
go.drugbank.com/drugs/DB14987ApprovedInvestigational[L56052, A275420] This skin disease occurs most frequently in children and can have an onset as early as within the first 2 years of life. … [L55042, A275424, A275420] As difamilast's mechanism of action involves the inhibition of PDE4, the inhibition leads to an increase in intracellular cyclic AMP and a subsequent decrease in the production
Bethanechol
go.drugbank.com/drugs/DB01019ApprovedBethanechol is a synthetic ester that was initially synthesized in 1935. … [A232905,L32539] As a cholinergic agent, bethanechol is similar in structure and pharmacological function to acetylcholine and is used in specific cases when stimulation of the parasympathetic nervous
Methenamine
go.drugbank.com/drugs/DB06799ApprovedInvestigationalVet approvedMethenamine is a heterocyclic organic compound with a cage-like structure similar to adamantane. In salt form it is used for the treatment of urinary tract infection (Example: methenamine hippurate which is the hippuric acid salt of meth...
Phenoxypropazine
go.drugbank.com/drugs/DB09251ApprovedWithdrawnIt was marketed as an antidepressant in 1961 but was later withdrawn in 1966 because of its hepatotoxic potential.
Prucalopride
go.drugbank.com/drugs/DB06480ApprovedInvestigational[A37348] The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies. … [A40254] Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009,[A40250] in Canada on December 7, 2011 and by the FDA on December 17, 2018.[L4880]
Ponesimod
go.drugbank.com/drugs/DB12016ApprovedInvestigational[A232079] Ponesimod was granted FDA approval on 18 March 2021.[L32709] … [A232079,L32709] Ponesimod was developed out of a need for a more selective modulator of sphingosine 1-phosphate receptor 1 than [fingolimod].
Florquinitau (18F)
go.drugbank.com/drugs/DB19215Approved[L64052] Florquinitau F 18, also known as MK-6240, was approved by the FDA on August 14, 2026 for PET of the brain in adults with cognitive impairment who are being evaluated for Alzheimer's disease … Florquinitau F 18 is a radioactive diagnostic drug used as a fluorine-18–labeled positron emission tomography (PET) tracer.
Tecovirimat
go.drugbank.com/drugs/DB12020ApprovedInvestigational[A35131,A35143] Tecovirimat was approved by the FDA in July 2018 as the first drug ever approved to treat smallpox. … However, there have been longstanding concerns that smallpox may be used as a bioweapon.[A35133,L3614] Tecovirimat is an antiviral drug that was identified via a high-throughput screen in 2002.
Grazoprevir
go.drugbank.com/drugs/DB11575ApprovedGrazoprevir is available as a fixed dose combination product with [DB11574] (tradename Zepatier) used for the treatment of chronic Hepatitis C. … Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) such as Grazoprevir.